[{"id":"c3ccbe27-3d9e-4190-a952-e531da2607f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890093","created_at":"2021-05-18T12:01:54.563Z","updated_at":"2025-02-25T13:49:09.588Z","phase":"Phase 1/2","brief_title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT04890093","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-20"},{"id":"4c23fea7-185d-4aea-b8bc-904da5a38f96","acronym":"","url":"https://clinicaltrials.gov/study/NCT03221400","created_at":"2021-01-18T15:53:56.456Z","updated_at":"2024-07-02T16:36:16.953Z","phase":"Phase 1/2","brief_title":"PEN-866 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT03221400","lead_sponsor":"Tarveda Therapeutics","biomarkers":" HSP90AA1","pipe":"","alterations":" ","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 08/29/2017","start_date":" 08/29/2017","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-02-17"}]